NVO vs RMD: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

NVO is the larger of the two ($169.20B market cap): the incumbent the market prices for continued execution (10.93x forward earnings, beta 0.37). RMD is the smaller challenger ($33.49B), actually pricier on forward earnings (18.00x): more room to run, but more to prove. If you believe in growth, RMD fits: analysts expect its revenue to rise 6% next year, against 1% for NVO. If you believe in paying less for profit, NVO fits: it trades at 10.93x forward earnings, against 18x for RMD.

NVO vs RMD: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricNVORMDWhat it tells you
Market cap$169.20B$33.49BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E10.9318.00Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E9.6921.68Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.370.76Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range11% of range59% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book5.175.63How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: NVO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how NVO and RMD affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVO and RMD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVO and RMD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Novo Nordisk (NVO) do?

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

Full NVO guide

What does ResMed (RMD) do?

ResMed sells the equipment and software used to treat sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions outside the hospital. The hardware side splits into flow generators (the AirSense and AirCurve device families, plus the Astral and Stellar life support ventilators) and the masks, cushions, tubing and filters patients replace on a rolling schedule. In fiscal 2026, the year ended June 30, 2026, Americas devices produced ~$1.77 billion and Americas masks and other ~$1.51 billion, while the rest of the world contributed ~$1.12 billion in devices and ~$572 million in masks. A third line, Residential Care Software, brought in ~$676 million from Brightree, MEDIFOX DAN and MatrixCare, the back office systems that home medical equipment dealers, out of hospital care providers and skilled nursing operators use for billing, resupply and scheduling. Roughly 11,370 employees support ~35 million cloud connected devices and ~37 million patients registered in AirView, the remote monitoring platform. Manufacturing is concentrated in Singapore, Sydney and Tijuana. The company is incorporated in Delaware, reports in US dollars, lists on the NYSE, and also trades in Australia as CHESS Depositary Interests.

Full RMD guide

NVO vs RMD: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
  • RMD drivers: Resupply, not new device placements, carries the growth; The Astral recall is a sized, dated hole rather than an open ended one.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and only about 6% in Q3, and the ADR down about 21% over the three months to November 20, 2026. For RMD, philips is the single largest competitive variable.

NVO or RMD: which should you pick?

If the story you believe is NVO's (GLP-1 obesity and diabetes demand), NVO is the more direct way to own it; if it is RMD's (Resupply, not new device placements, carries the growth), RMD is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVO and RMD guides.

NVO vs RMD: the full fundamentals

NVO. Novo Nordisk once commanded a premium pharma multiple on the strength of GLP-1 growth; at about 9.7x trailing and 11x forward earnings in November 2026 it trades at a discount that reflects slowing sales and share loss to Eli Lilly, even after a Q3 beat and a raised outlook. Trailing net income is lifted by an unusually large Q1 2026, which is one reason forward earnings estimates sit below trailing ones. Figures are reported in Danish kroner (market cap and the ADR dividend in dollars) and should be verified against the latest filings; the next report is due February 3, 2027.

RMD. At ~$238 the stock trades near 21.7x trailing GAAP earnings and ~18x forward estimates, below the ~30x it commanded before the GLP-1 debate began. Fiscal 2027 guidance of $5.75 billion to $5.85 billion of revenue and $12.00 to $12.25 of non-GAAP EPS absorbs the ~$75 million Astral headwind and the MatrixCare sale, and the first quarter's $2.91 of non-GAAP EPS puts the year on pace for the upper half of that range if it repeats, while revenue growth of ~5.9% sits inside the 5% to 7% core guide. Mature medtech multiple, double digit EPS growth target: that is the valuation argument in one line.

Headline figures (approximate, November 2026): NVO shows revenue (last four quarters) ~DKK 307 billion (+6% YoY in Q3 2026), revenue (2026 consensus) ~DKK 311 billion, net income (ttm) ~DKK 113 billion, gross margin ~83%; RMD shows revenue (trailing twelve months and fiscal 2026) ~$5.73 billion for the twelve months to September 30, 2026. Fiscal 2026, the twelve months ended June 30, 2026, brought ~$5.65 billion, up ~10% reported and ~8% in constant currency from ~$5.15 billion in fiscal 2025, ~$4.69 billion in fiscal 2024 and ~$4.22 billion in fiscal 2023. The September 2026 quarter, the first of fiscal 2027, produced ~$1.41 billion, up ~5.9% year on year and slightly above the ~$1.39 billion consensus, after the Astral sales suspension and the MatrixCare divestiture., earnings and margins Trailing twelve month GAAP net income of ~$1.59 billion and trailing GAAP EPS of ~$10.98, on a ~61.8% gross margin, ~34.0% operating margin and ~27.8% net margin. September 2026 quarter GAAP net income was ~$418 million, up ~23% year on year, and non-GAAP EPS was $2.91 against ~$2.67 expected. For fiscal 2026, GAAP diluted EPS was $10.43 and non-GAAP $11.17, up 17%, with GAAP gross margin of 61.1% and non-GAAP 62.4%; the fourth quarter carried a $42 million Astral provision., revenue mix (the line a screener misses) Fiscal 2026 devices totalled ~$2.89 billion (~$1.77 billion Americas, ~$1.12 billion rest of world), masks and other consumables ~$2.09 billion (~$1.51 billion Americas, ~$572 million rest of world), and Residential Care Software ~$676 million. Sleep and Breathing Health was ~$4.98 billion of the total. Masks grew 10% in the Americas and 12% internationally in the fourth quarter on a constant currency basis, against ~4% constant currency growth for software across the year., cash flow and balance sheet Trailing operating cash flow of ~$1.77 billion and free cash flow of ~$1.30 billion, per Yahoo Finance, against ~$1.81 billion and ~$1.65 billion for fiscal 2026. Cash of ~$1.01 billion against ~$611 million of total debt at September 30, 2026, a net cash position and a debt to equity ratio near 0.10. Cash was ~$1.47 billion at June 30, 2026, when ~$457 million of assets were held for sale for the pending MatrixCare disposal..

The bottom line: NVO vs RMD

NVO and RMD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined NVO and RMD exposure against your real portfolio. It is not an investment adviser.

Wondering how NVO or RMD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Novo Nordisk

Ask Walnut's AI anything about NVO and see how it fits what you own.

FAQ

What is the difference between NVO and RMD?

+

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. ResMed sells the equipment and software used to treat sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions outside the hospital. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is NVO or RMD the better stock?

+

Neither is universally better. NVO is the larger incumbent; RMD is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, NVO or RMD?

+

On forward P/E (as of November 2026), NVO trades at 10.93x and RMD at 18.00x, so NVO is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both NVO and RMD?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of NVO vs RMD?

+

NVO: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and only about 6% in Q3, and the ADR down about 21% over the three months to November 20, 2026. Oral competitors, including Lilly's Foundayo (backed by an EMA panel in October 2026) and Viking's Phase 3 pill, raise the pressure further. Manufacturing capacity has been a persistent constraint, limiting how much demand it can serve. US drug pricing, payer coverage decisions, and potential price negotiation add reimbursement risk to its largest market. As an ADR, NVO carries Danish krone currency exposure and is influenced by European regulation. Patent expiries and the eventual arrival of biosimilar or generic competition loom over the long-term semaglutide economics. Debt has also risen with the capacity build (about DKK 134 billion against about DKK 46 billion of cash at September 30, 2026), and trailing free cash flow of about DKK 33 billion is far below net income. RMD: Philips is the single largest competitive variable. Its Respironics business exited most of the US new device market after the 2021 foam recall and the subsequent consent decree, handing ResMed several points of share it did not have to compete for. Any credible return of Philips capacity to the US sleep market would meet a ResMed that has been pricing and allocating capital against a diminished rival for five years, and mask share, where switching costs are lowest, would be the first place to show it. The GLP-1 question is genuinely open. ResMed's 2.5 million patient study is observational and self published, and it measures behaviour in the early years of drug adoption rather than the steady state after sustained weight loss; a cohort that loses enough weight to fall below the diagnostic threshold would leave the resupply base entirely. Quality systems are the second live risk. A Class 1 designation on 168,069 Astral units invites FDA scrutiny that can extend past the specific defect into inspection findings, warning letters or a consent decree, and Philips is the cautionary case for how far that can go. Reimbursement adds pressure from the other side: most US revenue passes through home medical equipment suppliers paid by Medicare and commercial plans, so competitive bidding rounds and prior authorisation tightening compress the distributor before they reach ResMed. Manufacturing is concentrated in Singapore, Sydney and Tijuana, which leaves the gross margin exposed to tariffs and freight. Roughly a third of revenue is non-US, so a stronger dollar reduces reported growth. Finally, short interest near 10.9% in August and a 52 week range of $180.27 to $277.67, with the stock ~2.3% lower over a year even as trailing GAAP earnings grew to ~$1.59 billion and quarterly earnings rose ~23% year on year, mean sentiment, not fundamentals, has been setting the price. Revenue growth of ~5.9% in the September quarter, down from 9% in June, is the number the GLP-1 bears will point to until the Astral and MatrixCare effects lap.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NVO or RMD; figures are approximate and dated (as of November 2026). Verify current data before investing.